Report Date: Thursday, July 16, 2026, before market open | Call: 8:00 a.m. ET
UNH reports second-quarter results tomorrow against a dramatically different backdrop than a year ago. The stock has staged one of the sharpest rebounds in large-cap healthcare, up roughly 30% year-to-date and about 38% over the past 52 weeks, with the rally accelerating hard in the last three months. That comeback follows a brutal stretch: shares were cut in half from mid-2025 highs through the January 27, 2026 fourth-quarter report, when a disclosure of Optum Health loss-contract reserves, restructuring charges, and a weak initial 2026 outlook sent the stock down roughly 20% in a single session (from ~$352 to ~$283). The subsequent recovery has been driven by a new management team under returning CEO Stephen Hemsley, who took over in September 2025 and has pushed a turnaround built around repricing, cost discipline, and cultural/governance reset.
With the stock now trading near $418–430 and analyst sentiment having flipped from "Moderate Buy" to "Strong Buy" (19 of 26 covering analysts), expectations are elevated heading into tomorrow's print — options markets are pricing an implied move of roughly 6% on the release, and several sell-side firms (Morgan Stanley, KeyBanc, Truist) have recently lifted price targets into the $460–480 range ahead of results.
The current bullish setup traces directly to the April 21 first-quarter report, which materially beat expectations and triggered a full-year guidance raise. UnitedHealth Group reported first quarter 2026 results, with performance supported by actions taken over the last several quarters. Specifically:
On the call, CEO Hemsley characterized the quarter as broadly encouraging: "The first quarter unfolded largely as expected, reflecting actions taken in the past several months to drive consistent performance across each business... All of our major business segments exceeded plan for the quarter." CFO Wayne DeVeydt noted the beat was broad-based: "For the first quarter, we reported adjusted earnings per share of $7.23, well ahead of our expectations and backed by strong quality metrics, including cash flows and reserves."
Importantly, management reiterated the full-year earnings cadence, which is the key lens for interpreting tomorrow's Q2 number: "We continue to expect approximately 2/3 of earnings in the first half of the year and the remaining 1/3 in the second half... UnitedHealthcare earnings are over 75% weighted to the first half of the year." They also flagged that Q1's medical cost ratio benefited from favorable seasonality that should partially reverse: "The first quarter benefited modestly from seasonal dynamics, including lower-than-expected respiratory activity... we expect some of these dynamics to moderate as we move further into the second quarter, particularly given the impact of IRA-related changes to Part D seasonality." This is a critical expectations-setting data point — Q2 medical costs should sequentially step up versus Q1's unusually clean 83.9% ratio, and consensus reflects that (medical care ratio guided by the Street near 88.5%–88.6%).
The revenue-decline/EPS-growth combination is the story analysts will be probing — it implies the company is intentionally shrinking its book (exiting unprofitable Medicare, ACA and Medicaid contracts) while re-pricing aggressively to restore margin.
1. Medical cost trend — is pricing still ahead of utilization? Management's central 2026 thesis has been pricing MA at roughly a 10% cost trend assumption against underlying utilization running 7–8%, giving room for margin recovery. On the Q1 call, UnitedHealthcare CEO Tim Noel said: "We were talking about a 7% to 8% trend in Medicare Advantage with a pricing assumption of around 10% into 2026. We're seeing some modest favorability in the government programs... we're not seeing any inflection point, and we're really comfortable with the pricing posture that we had coming into 2026." Investors will want confirmation this gap persisted through Q2, especially given commentary about elevated physician billing intensity and rising acuity as an ongoing cost pressure Noel flagged in Q1.
2. Optum Health — margin recovery trajectory Optum Health was the epicenter of the Q4 2025 blowup (a negative 12% operating margin that quarter, driven by loss-contract reserves and a value-based-care portfolio unwind). Q1 2026 adjusted earnings of $1.3 billion came in well ahead of the ~$1.575B run-rate guide reference point cited on the call, but CFO DeVeydt cautioned this reflected favorable prior-year reserve development, not necessarily a new run rate. Watch for updates on: progress renegotiating or exiting underperforming provider delegation contracts (the "PDR," guided at north of $600 million for the year); and management's long-term Optum Health margin target of 6%–8%.
3. Optum Insight and Optum Rx — back-half weighting Both segments are guided to be more heavily weighted to H2 2026 (~60% of earnings), tied to AI-product transitions at Optum Insight and new client (800+) onboarding ramp at Optum Rx. Any signs of slippage here would be a negative surprise given how consensus is modeled.
4. Medicaid and ACA — known headwinds, watch for surprises Management has guided to continued Medicaid margin pressure/negative margins in 2026 on inadequate state rates, with recovery not expected until 2027, and a roughly one-third reduction in ACA individual membership as UNH exits unprofitable exchange business (with a pledge to refund any 2026 ACA profits). These are expected drags — the question is whether state rate negotiations are trending better or worse than plan.
5. Capital allocation and balance sheet UNH front-loaded its buyback (at least $2 billion by end of Q2, versus an original back-half-loaded $2.5B plan) given what management called a "deep intrinsic value discount," and is targeting a ~40% debt-to-capital ratio by H2 2026 (from 42.9% at Q1-end). Watch for confirmation buybacks were completed and any incremental M&A commentary (the pending Alegeus Technologies acquisition, expected to close in H2 2026).
6. AI investment payoff Management is running roughly $1.5 billion of AI investment through the P&L in 2026 (per Q1 commentary), pressuring the operating cost ratio (13.8% in Q1 vs. 12.4% a year ago) but expected to eventually drive productivity gains and Optum Insight commercialization. Investors will look for any incremental detail on ROI timing.
7. Overhangs: DOJ investigation and policy risk UnitedHealth continues to operate under an active DOJ investigation into its Medicare Advantage billing practices (both civil and criminal strands, with reports the probe has extended to Optum Rx and physician reimbursement practices), a persistent risk to sentiment and potential legal costs regardless of quarterly execution. Separately, CMS's proposed MA risk-adjustment model recalibration remains delayed (potentially to 2028) but was a source of analyst concern in Q1 given its outsized impact on chronic-condition coding relevant to Optum Health's value-based-care population.
UNH heads into Thursday's print riding a powerful narrative reversal — from a 2025 blow-up centered on Medicare Advantage cost overruns and a leadership crisis, to a 2026 "prove it" turnaround story under Hemsley that has already delivered one substantial beat-and-raise quarter. Consensus embeds a normalization in the medical cost ratio (up sequentially from Q1's unusually clean 83.9% toward ~88.5%) alongside continued margin expansion and intentional membership attrition. Given the stock's ~30% YTD run and a ~6% implied options move, the bar for a positive reaction is arguably higher than the raw EPS beat/miss — investors will be parsing MCR trend by product line, Optum Health's underlying (ex-reserve) profitability, and management's tone on full-year guidance durability rather than the headline number alone.